.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,750,210

« Back to Dashboard

Details for Patent: 6,750,210

Title: Formulation containing novel anti-inflammatory androstane derivative
Abstract:There is provided a pharmaceutical aerosol formulation comprising (i) a compound of formula (I) ##STR1## or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterized in that the compound of formula (I) or a solvate thereof is completely dissolved in the formulation.
Inventor(s): Biggadike; Keith (Stevanage, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:Feb 04, 2002
Application Number:10/066,964
Claims:1. A pharmaceutical aerosol formulation comprising (i) a compound of formula (I) ##STR9##

or a solvate thereof as medicament, (ii) a liquefied hydrofluoroalkane (HFA) gas as propellant; and characterised in that the compound of formula (I) or a solvate thereof is completely dissolved in the formulation.

2. A formulation according to claim 1 which contains a hydroxy containing co-solvent liquid as solubilising agent.

3. A formulation according to claim 2 wherein the solubilsing agent is ethanol.

4. A formulation according to claim 1 further comprising a low volatility component.

5. A formulation according to claim 4 wherein the low volatility component is glycerol.

6. A formulation according to claim 1 wherein the propellant gas is 1,1,1,2-tetrafluoroethane.

7. A pharmaceutical aerosol formulation according to claim 1 comprising (i) a compound of formula (I) ##STR10##

or a solvate thereof as medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant, (iii) a solubilising agent to assist the solubilisation of the medicament in the propellant and (iv) optionally a low volatility component; characterised in that the compound of formula (I) or a solvate thereof is completely dissolved in the formulation.

8. A formulation according to claim 7 which contains ethanol as solubilising agent and glycerol as low volatility component.

9. A formulation according to claim 1 wherein the solubilising agent is an oligolactic acid or derivative thereof.

10. A formulation according to claim 9 wherein the solubilising agent is a compound of formula (IIA)

or a derivative thereof, wherein n is an integer from 3 to 15.

11. A canister comprising a container containing a formulation according to claim 1 and fitted with a metering valve.

12. A canister comprising a container containing a formulation according to claim 7 and fitted with a metering valve.

13. A canister comprising a container containing a formulation according to claim 9 and fitted with a metering valve.

14. A metered dose inhaler comprising a canister according to claim 11 fitted with an actuator adapted for topical administration of the formulation to the lung.

15. A metered dose inhaler comprising a canister according to claim 11 fitted with an actuator adapted for topical administration of the formulation to the nose.

16. A metered dose inhaler comprising a canister according to claim 12 fitted with an actuator adapted for topical administration of the formulation to the lung.

17. A metered dose inhaler comprising a canister according to claim 12 fitted with an actuator adapted for topical administration of the formulation to the nose.

18. A metered dose inhaler comprising a canister according to claim 13 fitted with an actuator adapted for topical administration of the formulation to the lung.

19. A metered dose inhaler comprising a canister according to claim 13 fitted with an actuator adapted for topical administration of the formulation to the nose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc